Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Oct 07, 2026
TickeronGET DAILY SIGNALS
Why Is Quantum-Si (QSI) Stock Down -4.05% Today?

Why Is Quantum-Si (QSI) Stock Down -4.05% Today?

Key Takeaways

  • QSI shares were down roughly 4.05% intraday, trading near $1.17 versus a prior-session close of $1.22.
  • The decline reflects profit-taking and consolidation after a sharp, speculation-driven rally on interim data for the company's next-generation Proteus protein-sequencing platform.
  • A recent analyst downgrade to "Sell" and overbought technical conditions (RSI near 86) have added selling pressure.
  • Fundamental concerns persist: minimal revenue, ongoing losses, and a "transition year" with roughly $1.0 million in projected 2026 revenue.
  • Traders are watching upcoming third-quarter results and any further updates on the Proteus commercialization timeline.

Opening Summary

Quantum-Si Incorporated (QSI), a life sciences technology company developing single-molecule protein sequencing tools for proteomics research, was trading lower in Tuesday's session. The stock was down about 4.05% to roughly $1.17, compared with a prior close of $1.22. The move extends a multi-day pullback that began after the shares spiked on interim data from the company's Proteus platform, with markets citing profit-taking, an overbought technical setup, and lingering skepticism about near-term commercialization as the primary drivers.

Profit-Taking After a Speculative Run-Up

The dominant force behind the pullback appears to be investors locking in gains following an extraordinary short-term rally. Late in September, QSI shares surged after the company presented interim data at the World HUPO 2026 congress showing its Proteus platform generated roughly 30 times more peptide alignments than its current Platinum Pro system, with a substantially lower false-discovery rate. The stock climbed from below $1.00 to an intraday high above $1.55 within days, a move of more than 80% at its peak.

Such rapid, data-driven rallies in speculative, thinly commercialized life sciences names frequently attract momentum traders who exit once the initial catalyst cools. With no incremental news to sustain the advance, the stock has been unwinding those gains, falling in consecutive sessions from its early-October peak.

Analyst Downgrade and Fundamental Skepticism

The retreat has been compounded by a more cautious view from the sell side. Wall Street Zen downgraded QSI from "Hold" to "Sell" shortly after the surge, and commentary around the name has emphasized that the Proteus results are interim, company-reported, and not yet independently validated.

Underlying fundamentals remain challenging. The company is treating 2026 as a "transition year," guiding to revenue of approximately $1.0 million while it pivots toward the Proteus launch, which is not expected until 2027. Second-quarter revenue was minimal, and the company continues to post substantial net losses. Analysts and investors have noted that customers may be deferring purchases of the current Platinum instruments while awaiting Proteus, further pressuring near-term sales.

Market Context and Trading Activity

Trading volume has remained elevated relative to the stock's longer-term average, though it has eased from the extreme levels seen during the initial data-driven spike. The pullback has occurred as the shares pulled back from severely overbought technical conditions, with the relative strength index having reached levels above 85 during the rally. The stock has also traded around levels that carry listing-compliance significance: QSI received a Nasdaq notice earlier in 2026 after its share price fell below $1.00 for 30 consecutive business days, and the company has been working to sustain a bid above that threshold.

What Comes Next for QSI

Investors will be watching for the company's third-quarter results, as well as any additional performance milestones or validation data tied to the Proteus platform ahead of its targeted 2027 commercial launch. Management has emphasized a cash runway extending into 2028, but the investment case remains heavily dependent on execution and independent confirmation of the Proteus technology. Risks include potential launch delays, continued minimal revenue, ongoing cash burn, the possibility of future capital raises, and the stock's history of trading below the $1.00 listing threshold.

Trending AI Robots

For traders seeking a more systematic approach to volatile names like QSI, Tickeron's Trending AI Robots page offers a curated view of its top-performing AI trading bots. Tickeron provides hundreds of AI-driven trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots page to discover tools that may complement your own research process.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: QSI

Momentum Indicator for QSI turns positive, indicating new upward trend

QSI saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 81 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for QSI crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.

The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +6.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 157 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 94 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Bearish Trend Analysis

The 10-day RSI Indicator for QSI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 26 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 50 cases where QSI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for QSI turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 40 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.579) is normal, around the industry mean (4.204). P/E Ratio (-2.826) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 5.88B. The market cap for tickers in the group ranges from 837 to 190.62B. ABT holds the highest valuation in this group at 190.62B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -9%. NSPR experienced the highest price growth at 45%, while BDMD experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 29%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 49
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
QSI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
29 Business Park Drive
Phone
+1 866 688-7374
Employees
138
Web
https://www.quantum-si.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Analysts expect Q1 2026 revenue of approximately $8.5 billion, a roughly 5% increase from $8.1 billion in Q1 2025. Consensus adjusted earnings per share (EPS) forecast stands at $4.74, reflecting a potential decline from prior-year levels amid pricing pressures.
Analysts expect Q1 2026 adjusted EPS of around $1.61, down from prior year levels due to softer commodity prices. Consensus revenue forecast stands at approximately $14.5 billion, reflecting a year-over-year decline.
Why Is Quantum-Si (QSI) Stock Down -4.05% Today?